Patients with Alzheimer’s disease (AD) are often prescribed drugs for other conditions — including diabetes or high blood pressure — at the same doses as those without dementia. That practice might need to be reexamined in the wake of new mouse studies reported in ACS’ Molecular Pharmaceutics. The findings suggest that AD could alter absorption of medications from the digestive tract, so dosages might need to be adjusted for these patients.
- Rush researchers demonstrate success with new therapy for COVID-19
- Exploration of toxic Tiger Rattlesnake venom advances use of genetic science techniques
- Protected areas vulnerable to growing emphasis on food security
- Appearance, social norms keep students off Zoom cameras
- Genome editing to treat human retinal degeneration